A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Patients with Advanced Solid TumorsTherapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-506390-35-00
- Lead Sponsor
- Tesaro Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 840
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie TSR-042's PD-1 inhibition in CTIS2023-506390-35-00 for advanced solid tumors?
How does TSR-042's efficacy compare to pembrolizumab in CTIS2023-506390-35-00 for PD-L1 positive solid tumors?
Which biomarkers predict response to TSR-042 in CTIS2023-506390-35-00 for advanced solid tumor patients?
What are the immune-related adverse events and management strategies for TSR-042 in CTIS2023-506390-35-00?
What combination therapies with TSR-042 are being explored in CTIS2023-506390-35-00 for advanced solid tumors?